The patient comes first
For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.
Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.
Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.
Cooperation between Bayer and patient organizations is based on the following principles.
- In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
- Bayer and the patient organizations comply with international and national laws and regulations.
- Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
- Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.
Overview of cooperation with patient organizations in Europe in 2016
The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2016.
|Patient Organizations||Country of Organization's Office||Nature and Purpose of Support||Value in Euro||Travel costs in EURO|
|Agora (Platform of Organizations of People with Rheumatic Diseases in Southern Europe)||Cyprus||Support of PO regarding organization of their 5th Agora Conference, September 30 - October 02, 2016 in Bucharest, Romania||5.000,00||no|
|EHC (European Haemophlilia Consortium)||Belgium||One-year membership of the PO’s Corporate Giving Program. One-year membership of the EHCs Round Tables.||40.000,00||no|
|EuropaUomo||Belgium||Support activities of PO in 2016 regarding improvement the treatment and care of prostate cancer patients in Europe through improving information and support, and increasing the visibility of prostate cancer with policymakers and the public.||50.000,00||no|
|EURORDIS (European Rare Diseases Organisation)||France||Support of PO regarding organization of Black Pearl Evening in Brussels, February 23, 2016 (Platinum Partnership Level)||35.000,00||no|
|FEI (Federación Espanola de Ictus)||Spain||Support of PO regarding organization of their International Patient Meeting, May 10, 2016 in Barcelona, Spain||20.000,00||no|
|FEND (Foundation of European Nurses in Diabetes)||UK||Support activities of PO in 2016, support Annual Conference Munich September, 9-10, 2016||30.000,00||no|
|FESCA (Federation of European Scleroderma Associations)||Belgium||Support PO regarding 2016 World Scleroderma Day Activities||30.000,00||no|
|Hemofilievereniging /Association de L'Hémophilie||Belgium||Presentation for Bayer at Bayer Hemophilia Nurse Conference 2016, 10-12 June 2016 in Madrid, Spain||400,00||17,20|
|IAPB (International Agency for the Prevention of Blindness)||UK||Support of PO regarding the development of the “The Vision Atlas”, a compendium of key global data on blindness and vision impairment.||37.456,00||no|
|IAPB (International Agency for the Prevention of Blindness)||UK||Support of patron level membership||93.641,00||no|
|IAPB (International Agency for the Prevention of Blindness)||UK||Support of PO in organizing world sight day + general assembly meeting 2016||46.820,00||no|
|IDF (International Diabetes Federation)||Belgium||Support activities of PO in 2016 + support organization of "World Diabetes Day"||70.000,00||no|
|IDF (International Diabetes Federation)||Belgium||Support activities of PO to develop a patient information leaflet, to summarize key messages concerning eye health for the benefit of patients.||9.720,00||no|
|PHA (European Pulmonary Hypertension Association)||Austria||Support of PO regarding EU Policy Campaigns related to Pulmonary Hypertension||50.000,00||no|
|PHA (European Pulmonary Hypertension Association, UK Resource Centre)||UK||Presentation for Bayer at PH Patient Care Forum September 15-17, 2016 in Berlin, Germany||7.750,00||250,67|
|PHA Europe (European Pulmonary Hypertension Association)||Austria||Support of PO in organizing World PH Day 2016||100.000,00||no|
|SPAEN (Sarcoma Patients EuroNet Association)||Germany||Support activities of PO in 2016 regarding improvement the treatment and care of sarcoma patients in Europe through improving information and support, and increasing the visibility of sarcoma with policymakers and the public.||25.000,00||no|
|SPAEN (Sarcoma Patients EuroNet Association)||Germany||Organization will develop an international sarcoma patient online platform that provides publicly available information and education for patients and caregivers||29.750,00||no|
|SPAEN (Sarcoma Patients EuroNet Association)||Germany||Support of PO regarding preparation, planning and implementation of the "New Horizons GIST Conference"||31.500,00||no|
|Baltic States||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Belgium/Luxemburg (French)||Country website|
|Belgium/Luxemburg (Dutch)||Country website|
|Czech Republic||Country website|
|Estonia||Reports can be received from||UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
|Iceland||Reports can be received from||Bayer AB- Bayer Scandinavia
Gustav III:s Boulevard 56
169 26 Solna
|Romania||Reports can be received from||SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
|Serbia||Reports can be received from||Bayer Pharma d.o.o.
Omladinskih brigada 88b
|Slovenia||Reports can be received from||Bayer d.o.o.
Lucija Zlodi Gosnik
Donations in Germany
Social responsibility is at the core of Bayer’s identity. For us, donations are an effective way of expressing this responsibility and engaging in social action. Bayer provides financial resources and donations of drugs and cash to support projects worldwide dealing with health and scientific research.
We have published a list of projects that Bayer and its cooperating companies supported with donations in 2015. We published this list in compliance with the code of conduct of the association Voluntary Self-Regulation of the Pharmaceutical Industry ("Freiwillige Selbstkontrolle für die Arzneimittelindustrie"). Since the legally required disclosures are specific German requirements, the list of projects is only available in German: http://www.gesundheit.bayer.de/de/engagement/patientenorganisationen/projekte/index.php